The Governing Council of the University of Toronto

A multinational study analyzing data from over 230 million people across 20 global sites found that SARS-CoV-2 infection increases Guillain-Barré syndrome risk by approximately three times within six weeks of infection.

Neuropeutics Inc has been named the first recipient of the AbbVie Biotech Innovators Award for developing small molecules that prevent and reverse protein aggregation in neurodegenerative diseases.

Intrepid Labs has launched its Valiant platform, an AI-driven robotic system that reduces drug formulation development time from months to days, potentially improving clinical success rates.

Brain Cancer Canada has awarded $85,000 grants to two separate University of Toronto research teams investigating novel therapeutic approaches for glioblastoma, the most lethal brain cancer with less than 5% five-year survival rates.

A new artificial intelligence model, PROGRxN-BCa, trained on over 12,000 patients, outperforms current guideline-endorsed risk calculators for non-muscle invasive bladder cancer progression by approximately 10%.

• Zenflow's Spring System demonstrated 46% improvement in IPSS scores at 36 months post-placement, with 74% of patients achieving clinically significant symptom relief for benign prostatic hyperplasia. • The minimally invasive device maintained consistent efficacy over three years without compromising sexual function, positioning it as a leader in the emerging First-Line Interventional Therapy (FIT) category. • Results presented at the 2025 AUA Meeting represent the longest-term data among FIT interventions, with the company now advancing toward FDA approval through its multi-center BREEZE study.

A 7-year postmarketing analysis of lifitegrast ophthalmic solution 5% (Xiidra) confirms its favorable safety profile with no new safety signals identified across nearly 800,000 patient treatment years.

A new observational study found that people with diabetes taking GLP-1 drugs had more than twice the risk of developing neovascular age-related macular degeneration compared to those not taking the medications, with risk increasing from 0.1% to 0.2% after one year.

Unnecessary imaging scans for Medicare recipients alone generate up to 129 metric kilotons of carbon dioxide emissions annually, equivalent to powering a town of 70,000 people.

AmacaThera has formed a collaborative partnership with an unnamed global pharmaceutical company to develop a single-injection, long-acting biologic using its AmacaGel™ hydrogel delivery platform.